Cargando…
In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma
Background: Glioblastoma represents the most common primary brain tumor in adults. Despite technological advances, patients with this disease typically die within 1–2 years after diagnosis. In the search for novel therapeutics, drug repurposing has emerged as an alternative to traditional drug devel...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708851/ https://www.ncbi.nlm.nih.gov/pubmed/34959641 http://dx.doi.org/10.3390/ph14121241 |
_version_ | 1784622788982603776 |
---|---|
author | Halatsch, Marc-Eric Dwucet, Annika Schmidt, Carl Julius Mühlnickel, Julius Heiland, Tim Zeiler, Katharina Siegelin, Markus D. Kast, Richard Eric Karpel-Massler, Georg |
author_facet | Halatsch, Marc-Eric Dwucet, Annika Schmidt, Carl Julius Mühlnickel, Julius Heiland, Tim Zeiler, Katharina Siegelin, Markus D. Kast, Richard Eric Karpel-Massler, Georg |
author_sort | Halatsch, Marc-Eric |
collection | PubMed |
description | Background: Glioblastoma represents the most common primary brain tumor in adults. Despite technological advances, patients with this disease typically die within 1–2 years after diagnosis. In the search for novel therapeutics, drug repurposing has emerged as an alternative to traditional drug development pipelines, potentially facilitating and expediting the transition from drug discovery to clinical application. In a drug repurposing effort, the original CUSP9 and its derivatives CUSP9* and CUSP9v3 were developed as combinations of nine non-oncological drugs combined with metronomic low-dose temozolomide. Methods: In this work, we performed pre-clinical testing of CUSP9v3 in different established, primary cultured and stem-like glioblastoma models. In addition, eight patients with heavily pre-treated recurrent glioblastoma received the CUSP9v3 regime on a compassionate use basis in a last-ditch effort. Results: CUSP9v3 had profound antiproliferative and pro-apoptotic effects across all tested glioblastoma models. Moreover, the cells’ migratory capacity and ability to form tumor spheres was drastically reduced. In vitro, additional treatment with temozolomide did not significantly enhance the antineoplastic activity of CUSP9v3. CUSP9v3 was well-tolerated with the most frequent grade 3 or 4 adverse events being increased hepatic enzyme levels. Conclusions: CUSP9v3 displays a strong anti-proliferative and anti-migratory activity in vitro and seems to be safe to apply to patients. These data have prompted further investigation of CUSP9v3 in a phase Ib/IIa clinical trial (NCT02770378). |
format | Online Article Text |
id | pubmed-8708851 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87088512021-12-25 In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma Halatsch, Marc-Eric Dwucet, Annika Schmidt, Carl Julius Mühlnickel, Julius Heiland, Tim Zeiler, Katharina Siegelin, Markus D. Kast, Richard Eric Karpel-Massler, Georg Pharmaceuticals (Basel) Article Background: Glioblastoma represents the most common primary brain tumor in adults. Despite technological advances, patients with this disease typically die within 1–2 years after diagnosis. In the search for novel therapeutics, drug repurposing has emerged as an alternative to traditional drug development pipelines, potentially facilitating and expediting the transition from drug discovery to clinical application. In a drug repurposing effort, the original CUSP9 and its derivatives CUSP9* and CUSP9v3 were developed as combinations of nine non-oncological drugs combined with metronomic low-dose temozolomide. Methods: In this work, we performed pre-clinical testing of CUSP9v3 in different established, primary cultured and stem-like glioblastoma models. In addition, eight patients with heavily pre-treated recurrent glioblastoma received the CUSP9v3 regime on a compassionate use basis in a last-ditch effort. Results: CUSP9v3 had profound antiproliferative and pro-apoptotic effects across all tested glioblastoma models. Moreover, the cells’ migratory capacity and ability to form tumor spheres was drastically reduced. In vitro, additional treatment with temozolomide did not significantly enhance the antineoplastic activity of CUSP9v3. CUSP9v3 was well-tolerated with the most frequent grade 3 or 4 adverse events being increased hepatic enzyme levels. Conclusions: CUSP9v3 displays a strong anti-proliferative and anti-migratory activity in vitro and seems to be safe to apply to patients. These data have prompted further investigation of CUSP9v3 in a phase Ib/IIa clinical trial (NCT02770378). MDPI 2021-11-29 /pmc/articles/PMC8708851/ /pubmed/34959641 http://dx.doi.org/10.3390/ph14121241 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Halatsch, Marc-Eric Dwucet, Annika Schmidt, Carl Julius Mühlnickel, Julius Heiland, Tim Zeiler, Katharina Siegelin, Markus D. Kast, Richard Eric Karpel-Massler, Georg In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma |
title | In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma |
title_full | In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma |
title_fullStr | In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma |
title_full_unstemmed | In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma |
title_short | In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma |
title_sort | in vitro and clinical compassionate use experiences with the drug-repurposing approach cusp9v3 in glioblastoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708851/ https://www.ncbi.nlm.nih.gov/pubmed/34959641 http://dx.doi.org/10.3390/ph14121241 |
work_keys_str_mv | AT halatschmarceric invitroandclinicalcompassionateuseexperienceswiththedrugrepurposingapproachcusp9v3inglioblastoma AT dwucetannika invitroandclinicalcompassionateuseexperienceswiththedrugrepurposingapproachcusp9v3inglioblastoma AT schmidtcarljulius invitroandclinicalcompassionateuseexperienceswiththedrugrepurposingapproachcusp9v3inglioblastoma AT muhlnickeljulius invitroandclinicalcompassionateuseexperienceswiththedrugrepurposingapproachcusp9v3inglioblastoma AT heilandtim invitroandclinicalcompassionateuseexperienceswiththedrugrepurposingapproachcusp9v3inglioblastoma AT zeilerkatharina invitroandclinicalcompassionateuseexperienceswiththedrugrepurposingapproachcusp9v3inglioblastoma AT siegelinmarkusd invitroandclinicalcompassionateuseexperienceswiththedrugrepurposingapproachcusp9v3inglioblastoma AT kastricharderic invitroandclinicalcompassionateuseexperienceswiththedrugrepurposingapproachcusp9v3inglioblastoma AT karpelmasslergeorg invitroandclinicalcompassionateuseexperienceswiththedrugrepurposingapproachcusp9v3inglioblastoma |